Consumption of Bifidobacterium animalis subsp. lactis BB-12 impacts upper respiratory tract infection and the function of NK and T cells in healthy adults.
- 2016-03
- Molecular Nutrition & Food Research 60(5)
- Huicui Meng
- Yujin Lee
- Zhaoyong Ba
- Jiayu Peng
- Junli Lin
- Alexander S Boyer
- J. Fleming
- E. Furumoto
- R. Roberts
- P. Kris-Etherton
- C. Rogers
- PubMed: 26821116
- DOI: 10.1002/mnfr.201500665
Abstract
Scope: Probiotics can modulate immunity and reduce upper respiratory tract infections (URTI) in humans; however few studies have examined both outcomes in the same trial. The goal of the current study was to investigate the effect of Bifidobacterium animalis subsp. lactis BB-12, on natural killer (NK) and T-cell function in conjunction with self-reported cold/flu outcomes in healthy adults.
Methods and results: In a randomized, partially blinded, four-period crossover study, healthy adults (n = 30) were recruited, and received four treatments for 4 weeks in a random order: (i) yogurt smoothies alone (YS); smoothies with BB-12 added (ii) before (PRE) or (iii) after (POST) yogurt fermentation, or (iv) BB-12 capsule (CAP). NK- and T-cell function was assessed at baseline and after each treatment. Incidence and severity of cold/flu infection was quantified using self-reported URTI questionnaires. Participants on YS, PRE, or CAP treatments had elevated IL-2 secretion and NK-cell cytotoxicity, concurrently with fewer days with URTI. However, the POST treatment did not change immune outcomes or the severity of URTI.
Conclusion: The timing of BB-12 addition to yogurt smoothies in relation to the fermentation process influenced the impact of BB-12 on immune function and cold/flu severity in young healthy adults.
Trial registration: ClinicalTrials.gov NCT01399996.
Keywords: Delivery matrix; IL-2; Infection; NK cell; Probiotics; T cell.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bifidobacterium | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium | No Change in Immune Response | Neutral | Small |
Bifidobacterium | Reduced Upper Respiratory Infections | Beneficial | Moderate |
Bifidobacterium animalis | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium animalis | Increased IL-2 Secretion | Beneficial | Moderate |
Bifidobacterium animalis | Reduced Upper Respiratory Tract Infection Severity | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis | Increased IL-2 Secretion | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis | Unchanged Immune Function | Neutral | Small |
Bifidobacterium animalis subsp. lactis B420 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis B420 | Increased IL-2 Secretion | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis B420 | Reduced URTI Symptoms | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis BB-12 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis BB-12 | Reduced Upper Respiratory Tract Infection Days | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis BLC1 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis BLC1 | Reduced Upper Respiratory Tract Infection Severity | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis VK2 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium animalis subsp. lactis VK2 | Reduced Incidence of Upper Respiratory Tract Infections | Beneficial | Moderate |
Bifidobacterium bifidum BB01 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium bifidum BB-06 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium bifidum BB-06 | Reduced Upper Respiratory Tract Infection Severity | Beneficial | Moderate |
Bifidobacterium bifidum/lactis Bb-02 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium bifidum/lactis Bb-02 | Increased IL-2 Secretion | Beneficial | Moderate |
Bifidobacterium bifidum/lactis Bb-02 | Reduced Upper Respiratory Infections | Beneficial | Moderate |
Bifidobacterium lactis | Improved Immune Cell Function | Beneficial | Moderate |
Bifidobacterium lactis | Reduced Upper Respiratory Tract Infection Severity | Beneficial | Moderate |
Bifidobacterium lactis B420 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis B420 | Reduced Upper Respiratory Infections | Beneficial | Moderate |
Bifidobacterium lactis Bb-02 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis Bb-02 | Reduced Incidence of Upper Respiratory Tract Infections | Beneficial | Moderate |
Bifidobacterium lactis BB-12 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium lactis BB-12 | Reduced Duration of Upper Respiratory Tract Infection | Beneficial | Moderate |
Bifidobacterium lactis BB-12 | Unchanged Immune Function | Neutral | Small |
Bifidobacterium lactis BL818 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis BL818 | No Change in Immune Outcomes | Neutral | Small |
Bifidobacterium lactis BL818 | Reduced Incidence of Upper Respiratory Tract Infections | Beneficial | Moderate |
Bifidobacterium lactis BLA80 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium lactis BLA80 | Increased IL-2 Secretion | Beneficial | Moderate |
Bifidobacterium lactis BLC-1 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium lactis BLC-1 | Increased IL-2 Secretion | Beneficial | Moderate |
Bifidobacterium lactis BLC-1 | Reduced Duration of Upper Respiratory Tract Infection | Beneficial | Moderate |
Bifidobacterium lactis BS01 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis BS01 | Reduced Upper Respiratory Infections | Beneficial | Moderate |
Bifidobacterium lactis HA-194 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis HA-194 | Reduced Upper Respiratory Symptoms | Beneficial | Moderate |
Bifidobacterium lactis ISS Bif | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis ISS Bif | Reduced Upper Respiratory Infections | Beneficial | Moderate |
Bifidobacterium lactis R101-8 | Improved Immune Function | Beneficial | Moderate |
Bifidobacterium lactis UABla-12 | Improved NK-Cell Cytotoxicity | Beneficial | Moderate |
Bifidobacterium lactis UABla-12 | Improved Regulatory T Cell Function | Beneficial | Moderate |
Bifidobacterium lactis UABla-12 | Reduced Duration of Upper Respiratory Tract Infection | Beneficial | Moderate |
Bifidobacterium lactis VK2 | Reduced Upper Respiratory Tract Infection Severity | Beneficial | Moderate |
Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.
Send us an email at support@pillser.com.